Orchestra BioMed Holdings (OBIO) EBIT (2022 - 2025)
Historic EBIT for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$20.3 million.
- Orchestra BioMed Holdings' EBIT fell 2429.94% to -$20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year decrease of 2517.76%. This contributed to the annual value of -$64.3 million for FY2024, which is 2484.18% down from last year.
- As of Q3 2025, Orchestra BioMed Holdings' EBIT stood at -$20.3 million, which was down 2429.94% from -$19.3 million recorded in Q2 2025.
- Over the past 5 years, Orchestra BioMed Holdings' EBIT peaked at -$5.1 million during Q1 2022, and registered a low of -$20.3 million during Q3 2025.
- Over the past 4 years, Orchestra BioMed Holdings' median EBIT value was -$14.4 million (recorded in 2024), while the average stood at -$13.8 million.
- As far as peak fluctuations go, Orchestra BioMed Holdings' EBIT crashed by 12513.65% in 2023, and later crashed by 1251.72% in 2024.
- Quarter analysis of 4 years shows Orchestra BioMed Holdings' EBIT stood at -$9.8 million in 2022, then fell by 26.99% to -$12.5 million in 2023, then plummeted by 33.62% to -$16.7 million in 2024, then decreased by 21.8% to -$20.3 million in 2025.
- Its EBIT stands at -$20.3 million for Q3 2025, versus -$19.3 million for Q2 2025 and -$18.9 million for Q1 2025.